Loading…
Lobbying Spend
—
Filings
198
Firms Hired
7
Active Period
2002–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Improving Access To Affordable Prescription Drugs Act
2017 · fourth_quarter · Firm: LOPER CONSULTING LLC
Issues related to affordability and pricing of pharmaceuticals including S.771 Improving Access to Affordable Prescription Drugs Act. Issues related to opioids
Client expense: — · Firm income: $50,000
Matched citations: S.771
American Health Care Act of 2017
2017 · third_quarter · Firm: LOPER CONSULTING LLC
Issues related to affordability and pricing of pharmaceuticals including S.771 Improving Access to Affordable Prescription Drugs Act. FDA user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement. Issues related to H.R. 1628, the American Health Care Act. Better Care Reconciliation Act (BCRA) Issues related to opioids
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1628
Improving Access To Affordable Prescription Drugs Act
2017 · third_quarter · Firm: LOPER CONSULTING LLC
Issues related to affordability and pricing of pharmaceuticals including S.771 Improving Access to Affordable Prescription Drugs Act. FDA user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement. Issues related to H.R. 1628, the American Health Care Act. Better Care Reconciliation Act (BCRA) Issues related to opioids
Client expense: — · Firm income: $50,000
Matched citations: S.771
American Health Care Act of 2017
2017 · second_quarter · Firm: LOPER CONSULTING LLC
Issues related to affordability and pricing of pharmaceuticals including S.771 Improving Access to Affordable Prescription Drugs Act. FDA user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement. Issues related to H.R. 1628, the American Health Care Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1628
Improving Access To Affordable Prescription Drugs Act
2017 · second_quarter · Firm: LOPER CONSULTING LLC
Issues related to affordability and pricing of pharmaceuticals including S.771 Improving Access to Affordable Prescription Drugs Act. FDA user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement. Issues related to H.R. 1628, the American Health Care Act.
Client expense: — · Firm income: $50,000
Matched citations: S.771
American Health Care Act of 2017
2017 · first_quarter · Firm: LOPER CONSULTING LLC
Issues related to affordability and pricing of pharmaceuticals including S.771 Improving Access to Affordable Prescription Drugs Act. FDA user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement. Issues related to H.R. 1628, the American Health Care Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1628
Improving Access To Affordable Prescription Drugs Act
2017 · first_quarter · Firm: LOPER CONSULTING LLC
Issues related to affordability and pricing of pharmaceuticals including S.771 Improving Access to Affordable Prescription Drugs Act. FDA user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement. Issues related to H.R. 1628, the American Health Care Act.
Client expense: — · Firm income: $50,000
Matched citations: S.771
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels S. 484 and HR 1353 PATIENTS Act of 2015 Senate HELP working group on Innovation for Healthier Americans
Client expense: — · Firm income: $50,000
Matched citations: HR 1353
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels S. 484 and HR 1353 PATIENTS Act of 2015 Senate HELP working group on Innovation for Healthier Americans
Client expense: — · Firm income: $50,000
Matched citations: S. 484
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels S. 484 and HR 1353 PATIENTS Act of 2015 21st Century Cures/innovation
Client expense: — · Firm income: $50,000
Matched citations: HR 1353
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels S. 484 and HR 1353 PATIENTS Act of 2015 21st Century Cures/innovation
Client expense: — · Firm income: $50,000
Matched citations: S. 484
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels S. 484 and HR 1353 PATIENTS Act of 2015 Senate HELP working group on Innovation for Healthier Americans
Client expense: — · Firm income: $50,000
Matched citations: HR 1353
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels S. 484 and HR 1353 PATIENTS Act of 2015 Senate HELP working group on Innovation for Healthier Americans
Client expense: — · Firm income: $50,000
Matched citations: S. 484
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels S. 484 and HR 1353 PATIENTS Act of 2015 Senate HELP working group on Innovation for Healthier Americans
Client expense: — · Firm income: $50,000
Matched citations: HR 1353
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels S. 484 and HR 1353 PATIENTS Act of 2015 Senate HELP working group on Innovation for Healthier Americans
Client expense: — · Firm income: $50,000
Matched citations: S. 484
H.R.2029 - Consolidated Appropriations Act, 2016 Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels S. 484 and HR 1353 PATIENTS Act of 2015 Senate HELP working group on Innovation for Healthier Americans
Client expense: — · Firm income: $50,000
Matched citations: HR 1353
Consolidated Appropriations Act, 2016
2015 · fourth_quarter · Firm: LOPER CONSULTING LLC
H.R.2029 - Consolidated Appropriations Act, 2016 Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels S. 484 and HR 1353 PATIENTS Act of 2015 Senate HELP working group on Innovation for Healthier Americans
Client expense: — · Firm income: $50,000
Matched citations: H.R.2029
H.R.2029 - Consolidated Appropriations Act, 2016 Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels S. 484 and HR 1353 PATIENTS Act of 2015 Senate HELP working group on Innovation for Healthier Americans
Client expense: — · Firm income: $50,000
Matched citations: S. 484
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels S. 484 and HR 1353 PATIENTS Act of 2015 Senate HELP working group on Innovation for Healthier Americans
Client expense: — · Firm income: $50,000
Matched citations: HR 1353
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels S. 484 and HR 1353 PATIENTS Act of 2015 Senate HELP working group on Innovation for Healthier Americans
Client expense: — · Firm income: $50,000
Matched citations: S. 484
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels HR 6 21st Century Cures Senate HELP working group on Innovation for Healthier Americans
Client expense: — · Firm income: $50,000
Matched citations: HR 6
S 2948 Medicaid Generic Drug Price Fainess Act H.R.1353 PATIENT Act of 2015 Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels
Client expense: — · Firm income: $50,000
Matched citations: H.R.1353
Medicaid Generic Drug Price Fairness Act
2015 · first_quarter · Firm: LOPER CONSULTING LLC
S 2948 Medicaid Generic Drug Price Fainess Act H.R.1353 PATIENT Act of 2015 Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels
Client expense: — · Firm income: $50,000
Matched citations: S 2948
Medicaid Generic Drug Price Fairness Act
2014 · fourth_quarter · Firm: LOPER CONSULTING LLC
Lobbied on issues related to abuse deterrent formulation of drugs &prescription drug abuse. FDA proposed rule on generic drug labels S. 2948 Medicaid Generic Drug Price Fairness Act Lobbied on a policy related to incentives for New Therapeutic Entities
Client expense: — · Firm income: $50,000
Matched citations: S. 2948
Air Traffic Control Tower Funding Restoration Act
2014 · third_quarter · Firm: RUBICON ADVISORS, LLC
Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100 Affodable Health Choices Act
Client expense: — · Firm income: $120,000
Matched citations: H.R. 1432
Source: Senate LDA